ArticleInternational journal of cardiology. Heart & vasculature2026
Mortality risk stratification in contemporary myocardial infarction-related cardiogenic shock: development of AMICS-ADMIT prediction model and benchmarking of established scores.
Article in International journal of cardiology. Heart & vasculature, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Mortality risk stratification in acute myocardial infarction complicated by cardiogenic shock (AMI-CS) remains challenging with heterogeneous temporary mechanical circulatory support (tMCS) use. We developed and temporally validated the admission-based AMICS-ADMIT model and bedside score and benchmarked them against established scores. Methods: This retrospective single-centre study, reported according to TRIPOD+AI, included 479 consecutive patients with AMI-CS undergoing percutaneous coronary intervention (PCI) between January 2017 and July 2025. The primary endpoint was in-hospital mortality. AMICS-ADMIT was developed using multivariable logistic regression in the 2017-2022 cohort, internally evaluated by bootstrap resampling, and temporally validated in the 2023-2025 cohort. Missing data were multiply imputed. Performance was assessed using discrimination, calibration, and Brier scores. Benchmarking against CardShock, IABP-SHOCK II, and GRACE was restricted to temporal validation; tMCS-stratified performance was exploratory. Results: In-hospital mortality was 42.6% (204/479). The final model included age, left ventricular ejection fraction, prior cardiopulmonary resuscitation, estimated glomerular filtration rate, vasoactive-inotropic score, and ST-segment elevation status. The continuous model achieved AUCs of 0.809 (95% CI 0.764-0.855) in development and 0.834 (95% CI 0.769-0.899) in temporal validation, with Brier scores of 0.176 and 0.167 and favourable calibration. The bedside score achieved AUCs of 0.777 (95% CI 0.728-0.826) and 0.775 (95% CI 0.699-0.851), respectively, with stepwise mortality separation across predefined risk categories. Discrimination did not differ significantly from CardShock, IABP-SHOCK II, or GRACE. Conclusions: AMICS-ADMIT showed stable temporal performance and clinically interpretable early risk stratification in contemporary PCI-treated AMI-CS. External multicentre validation is required before clinical implementation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.